Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma

Inclusion Criteria: * Participants must have clinical diagnosis of cutaneous squamous cell carcinoma or metastatic squamous cell carcinoma with cutaneous involvement supported by histological evaluation of skin lesions based upon available clinical data including pathology reports from non-study institution (if applicable) * Participants must have visible cutaneous disease. Skin lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * A single lesion is amenable to placement of one or multiple devices in terms of lesion size and location, as assessed by dermatologist (minimum lesion diameter of 1.0 cm). * Washout period from previous treatments is not necessary. * Age minimum of age 18. Because of limited incidence of cutaneous squamous cell carcinoma in the pediatric population, children are excluded from this study. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). * Participants will undergo laboratory testing within 28 days prior to the procedure. Participants must have marrow function as defined below: absolute neutrophil count ≥500/mcL platelets ≥50,000/mcL * Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * P…